Aquestive Therapeutics Resubmits NDA For Anaphylm Sublingual Film

Aquestive Therapeutics resubmitted its New Drug Application to the FDA for Anaphylm, a sublingual film intended to treat Type I allergic reactions including anaphylaxis. The resubmission is supported by positive topline data, advancing the product toward a potential FDA decision and creating a meaningful regulatory catalyst for AQST.